CL2019000277A1 - Tratamiento conjunto contra el cáncer. - Google Patents

Tratamiento conjunto contra el cáncer.

Info

Publication number
CL2019000277A1
CL2019000277A1 CL2019000277A CL2019000277A CL2019000277A1 CL 2019000277 A1 CL2019000277 A1 CL 2019000277A1 CL 2019000277 A CL2019000277 A CL 2019000277A CL 2019000277 A CL2019000277 A CL 2019000277A CL 2019000277 A1 CL2019000277 A1 CL 2019000277A1
Authority
CL
Chile
Prior art keywords
against cancer
joint treatment
treatment against
tgfb
cancer
Prior art date
Application number
CL2019000277A
Other languages
English (en)
Inventor
Kin-Ming Lo
Yan Lan
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CL2019000277A1 publication Critical patent/CL2019000277A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1077—Beam delivery systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCIÓN SE RELACIONA DE MANERA GENERAL CON UN TRATAMIENTO CONJUNTO, PARA TRATAR CÁNCER, PARTICULARMENTE CON UNA COMBINACIÓN DE: (I) UNA MOLÉCULA BIFUNCIONAL QUE COMPRENDE UN TGFB O FRAGMENTO DEL MISMO CAPAZ DE UNIR TGFB Y UN ANTICUERPO, O FRAGMENTO DEL MISMO QUE UNE ANTÍGENO, QUE SE UNE A UNA PROTEÍNA DE PUNTO DE VERIFICACIÓN INMUNITARIA, COMO POR EJEMPLO LIGANDO 1 DE MUERTE PROGRAMADA (PD-L1) Y (II) POR LO MENOS UN AGENTE TERAPÉUTICO ADICIONAL CONTRA EL CÁNCER.
CL2019000277A 2016-08-12 2019-02-01 Tratamiento conjunto contra el cáncer. CL2019000277A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662374621P 2016-08-12 2016-08-12

Publications (1)

Publication Number Publication Date
CL2019000277A1 true CL2019000277A1 (es) 2019-07-05

Family

ID=59686928

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000277A CL2019000277A1 (es) 2016-08-12 2019-02-01 Tratamiento conjunto contra el cáncer.

Country Status (16)

Country Link
US (2) US20180118832A1 (es)
EP (1) EP3497130B1 (es)
JP (1) JP7573365B2 (es)
KR (3) KR20250028537A (es)
CN (1) CN109641963A (es)
AU (2) AU2017310027A1 (es)
BR (1) BR112019001818A2 (es)
CA (1) CA3031168A1 (es)
CL (1) CL2019000277A1 (es)
ES (1) ES2905663T3 (es)
IL (1) IL264730B2 (es)
MX (1) MX2019001503A (es)
PH (1) PH12019500270A1 (es)
RU (1) RU2019106663A (es)
SG (1) SG11201901126UA (es)
WO (1) WO2018029367A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2921805C (en) 2013-08-22 2023-03-07 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
HK1256638A1 (zh) 2015-08-04 2019-09-27 Acceleron Pharma Inc. 用於治疗骨髓增生性病症的方法
LT3628049T (lt) 2017-05-04 2023-08-25 Acceleron Pharma Inc. Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
US20210015857A1 (en) * 2018-03-23 2021-01-21 The University Of Western Australia Method for immunotherapy drug treatment
CN112512576A (zh) * 2018-05-04 2021-03-16 默克专利有限公司 PD-1/PD-L1、TGFβ和DNA-PK联合抑制用于治疗癌症
EP3813868A4 (en) * 2018-05-15 2022-03-02 Merck Patent GmbH Dosing regimens for targeted tgf-b inhibition for use in treating cancer in treatment naive subjects
EP3806842A4 (en) * 2018-06-13 2022-03-16 Merck Patent GmbH Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment
SG11202013190YA (en) * 2018-07-02 2021-01-28 Merck Patent Gmbh Combination therapy with targeted tgf-b inhibition for treatment of advanced non-small cell lung cancer
WO2020014285A2 (en) * 2018-07-09 2020-01-16 Intrexon Corporation Fusion constructs and methods of using thereof
BR112021009835A2 (pt) * 2018-11-30 2021-08-17 Jiangsu Hengrui Medicine Co., Ltd. anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
AR117918A1 (es) 2019-01-30 2021-09-01 Scholar Rock Inc COMPLEJOS-ESPECÍFICOS LTBP INHIBIDORES DE TGFb Y SUS USOS
EP3693974A1 (en) * 2019-02-07 2020-08-12 Koninklijke Philips N.V. Identifying responsiveness to radio-immuno combination therapy
CA3135988C (en) 2019-06-10 2024-11-19 Shandong Boan Biotechnology Co., Ltd. Bifunctional fusion protein against PD-L1 and TGFS and its use
US10851157B2 (en) * 2019-07-01 2020-12-01 Gensun Biopharma, Inc. Antagonists targeting the TGF-β pathway
CN112442132A (zh) * 2019-09-05 2021-03-05 复旦大学 靶向肿瘤的重组双功能融合蛋白及其应用
BR112022004563A2 (pt) * 2019-09-12 2022-06-07 Sirnaomics Inc Coliberação de sirna tgf-ß e sirna pdl1 para tratar câncer
CN112574314A (zh) * 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 一种融合蛋白及其应用
US11802145B2 (en) 2019-10-21 2023-10-31 Nanjing Leads Biolabs Co., Ltd. Recombinant protein targeting PD-1 and TGFß
EP4051279A1 (en) * 2019-11-01 2022-09-07 Ares Trading S.A. COMBINED INHIBITION OF PD-1, TGFß AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER
EP4054633A1 (en) * 2019-11-05 2022-09-14 Merck Patent GmbH Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
AU2020402496A1 (en) * 2019-12-11 2022-06-16 WuXi Biologics Ireland Limited Bi-functional antibody against PD-L1 and TGFβ
EP3838260A1 (en) 2019-12-20 2021-06-23 Ares Trading S.A. Igg:tgf rii fusion protein composition
JP7730817B6 (ja) 2019-12-20 2025-09-26 アレス トレーディング ソシエテ アノニム ＩｇＧ：ＴＧＦβＲＩＩ融合タンパク質組成物
AU2021205440A1 (en) 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof
US20230057012A1 (en) 2020-01-11 2023-02-23 Scholar Rock, Inc. Tgfb inhibitors and use thereof
US20230072133A1 (en) * 2020-02-25 2023-03-09 WuXi Biologics Ireland Limited A bifunctional fusion protein and uses thereof
AU2021256925A1 (en) * 2020-04-14 2022-11-03 Ares Trading S.A. Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein
WO2021209458A1 (en) 2020-04-14 2021-10-21 Ares Trading S.A. Combination treatment of cancer
EP4178680A4 (en) 2020-07-10 2024-07-31 Precigen, Inc. FUSION CONSTRUCTS AND THEIR METHODS OF USE
US20230365653A1 (en) * 2020-07-24 2023-11-16 Mabwell (shanghai) Bioscience Co., Ltd. Tgf-beta rii mutant and fusion protein thereof
WO2022063193A1 (zh) * 2020-09-24 2022-03-31 上海齐鲁制药研究中心有限公司 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
US20230372319A1 (en) 2020-11-02 2023-11-23 Ares Trading S.A. Combination Treatment of Cancer
WO2022090527A1 (en) 2020-11-02 2022-05-05 Ares Trading S.A. Combination treatment of cancer
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
IL308163A (en) 2021-05-03 2024-01-01 Merck Patent Gmbh Her2 targeting fc antigen binding fragment-drug conjugates
WO2022248380A1 (en) 2021-05-25 2022-12-01 Merck Patent Gmbh Egfr targeting fc antigen binding fragment-drug conjugates
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
WO2022258622A1 (en) 2021-06-07 2022-12-15 Ares Trading S.A. Combination treatment of cancer
GB202215997D0 (en) * 2022-10-28 2022-12-14 Io Biotech Aps Therapy
WO2024149237A1 (zh) 2023-01-09 2024-07-18 北京拓界生物医药科技有限公司 TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
AU2002248571B2 (en) 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
HRP20201595T1 (hr) * 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
CN110563850A (zh) * 2012-04-30 2019-12-13 比奥孔有限公司 靶向/免疫调节性融合蛋白及其制造方法
WO2013181452A1 (en) * 2012-05-31 2013-12-05 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
US9676863B2 (en) * 2014-02-10 2017-06-13 Merck Patent Gmbh Targeted TGFβ inhibitors

Also Published As

Publication number Publication date
KR20190039200A (ko) 2019-04-10
JP7573365B2 (ja) 2024-10-25
RU2019106663A (ru) 2020-09-14
IL264730A (en) 2019-03-31
CA3031168A1 (en) 2018-02-15
PH12019500270A1 (en) 2019-07-01
ES2905663T3 (es) 2022-04-11
US20180118832A1 (en) 2018-05-03
IL264730B1 (en) 2024-05-01
BR112019001818A2 (pt) 2019-05-07
EP3497130B1 (en) 2021-10-27
EP3497130A1 (en) 2019-06-19
MX2019001503A (es) 2019-06-03
WO2018029367A1 (en) 2018-02-15
RU2019106663A3 (es) 2020-11-26
KR20230125859A (ko) 2023-08-29
KR20250028537A (ko) 2025-02-28
SG11201901126UA (en) 2019-03-28
AU2024219446A1 (en) 2024-09-26
CN109641963A (zh) 2019-04-16
AU2017310027A1 (en) 2019-01-31
IL264730B2 (en) 2024-09-01
US20220017621A1 (en) 2022-01-20
JP2019527706A (ja) 2019-10-03

Similar Documents

Publication Publication Date Title
CL2019000277A1 (es) Tratamiento conjunto contra el cáncer.
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
CY1123858T1 (el) Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων
CL2017001920A1 (es) Anticuerpos humanos contra glicoproteína del virus ébola
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CO2018003542A2 (es) Anticuerpo anti-garp
EA202091540A1 (ru) Антитела к lilrb2
MX2020009861A (es) Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
MX388015B (es) Un anticuerpo anti-csf1r y al menos un agente inmuno-estimulador para usarse en el tratamiento de cáncer.
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
SV2017005380A (es) Tratamientos conjuntos con anticuerpos anti cd40
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
MX2021001268A (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
CO2019011640A2 (es) Métodos y composiciones para la reducción de la inmunogenicidad
MX389342B (es) Un anticuerpo anti-cd20 en combinación con un inhibidor de bcl-2 y un inhibidor de mdm2 para usarse en el tratamiento de cáncer.
CO2019009586A2 (es) Anticuerpos anti-gitr y métodos de uso de los mismos
EA201792300A1 (ru) Комбинации иммуноконъюгата к cd37 и антитела к cd20
MX2023014921A (es) Anticuerpo anti-cd154 con caracteristicas de union, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana.
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
CY1126032T1 (el) Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap
MX2024003627A (es) Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus metodos de uso.
MX2019011958A (es) Proteína de fusión activadora de células nk, célula nk, y composición farmacéutica que las incluye.
CL2019000846A1 (es) Proteína terapéutica.